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Abstract
Background—The presence and severity of coronary artery calcified plaque (CAC) differs
markedly between individuals of African and European descent, suggesting that admixture
mapping (AM) may be informative for identifying genetic variants associated with subclinical
cardiovascular disease (CVD).
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Methods and Results—AM of CAC was performed in 1,040 unrelated African Americans
with type 2 diabetes mellitus from the African American-Diabetes Heart Study (AA-DHS), Multi-
Ethnic Study of Atherosclerosis (MESA), and Family Heart Study (FamHS) using the Illumina
custom ancestry informative marker (AIM) panel. All cohorts obtained computed tomography
scanning of the coronary arteries using identical protocols. For each AIM, the probability of
inheriting 0, 1, and 2 copies of a European-derived allele was determined. Linkage analysis was
performed by testing for association between each AIM using these probabilities and CAC,
accounting for global ancestry, age, gender and study. Markers on 1p32.3 in the GLIS1 gene
(rs6663966, LOD=3.7), 1q32.1 near CHIT1 (rs7530895, LOD=3.1), 4q21.2 near PRKG2
(rs1212373, LOD=3.0) and 11q25 in the OPCML gene (rs6590705, LOD=3.4) had statistically
significant LOD scores, while markers on 8q22.2 (rs6994682, LOD=2.7), 9p21.2 (rs439314,
LOD=2.7), and 13p32.1 (rs7492028, LOD=2.8) manifested suggestive evidence of linkage. These
regions were uniformly characterized by higher levels of European ancestry associating with
higher levels or odds of CAC. Findings were replicated in 1,350 AAs without diabetes and 2,497
diabetic European Americans from MESA and the Diabetes Heart Study.
Conclusions—Fine mapping these regions will likely identify novel genetic variants that
contribute to CAC and clarify racial differences in susceptibility to subclinical CVD.
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Introduction
Despite similar or more detrimental cardiovascular disease (CVD) risk factor profiles,
African Americans (AAs) have markedly lower levels of coronary artery calcified
atherosclerotic plaque (CAC), relative to European Americans (EAs)1, 2. This observation is
consistent in persons with and without type 2 diabetes mellitus (T2DM)3, 4 and suggests that
CVD risk factors have differential impacts on atherosclerosis based upon ethnicity. The
underlying cause(s) of ethnic differences in CAC are not well understood and likely reflect
the interplay between multiple genetic and non-conventional CVD risk factors5. Wassel et
al.6 reported positive association between CAC in AAs and proportion of European
ancestry. We performed admixture mapping in 1,040 AAs with T2DM to determine
genomic regions contributing to ethnic differences in subclinical CVD. T2DM led to higher
levels of CAC with the potential for improved power to better discriminate susceptible
individuals. Regional admixture mapping (RAM) or mapping by admixture linkage
disequilibrium (MALD), is a gene mapping tool used to identify genetic variants associated
with differences in prevalence and/or distribution of a trait between two or more ancestral
populations7. The premise of RAM is that if a genetic variant underlies ethnic differences in
disease then it will be easier to map the location of that variant in a recently admixed
population relative to panmictic ancestral populations. The proportion of alleles at the
marker locus that have ancestry from the high-risk population will be higher in affected
individuals then expected by chance, assuming no other influential evolutionary forces
(genetic selection or drift).
RAM successfully identified disease genes or loci involved in various complex traits and
diseases8–10. Recent methodological developments revealed that combining admixture
mapping and genetic association testing can lead to improved power11.
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The discovery data were pooled from three study cohorts where CAC was quantified by
cardiac computed tomography (CT) using identical protocols12. Statistical analyses included
1,040 unrelated individuals; 22 samples were removed because they failed quality control
(QC).
African American-Diabetes Heart Study (AA-DHS)—The AA-DHS contained AAs
with T2DM recruited from two Wake Forest School of Medicine (WFSM) studies: the
Diabetes Heart Study (DHS) and African American-DHS. DHS is a cross-sectional study of
EA and AA families with siblings concordant for T2DM. AA-DHS started after DHS and
enrolled only unrelated AAs. AA-DHS objectives were to improve understanding of the
striking ethnic differences in CAC observed between AAs and EAs. T2DM was diagnosed
after the age of 30 years in the absence of diabetic ketoacidosis. The DHS “family of
studies” is described in Bowden et al.13. Subjects who underwent prior coronary artery
bypass surgery were not included in the MALD analysis, as the CAC mass score could be
impacted14. Those with prior myocardial infarction or stroke were included. The final
analysis included 635 unrelated AAs obtained by selecting all AA-DHS participants and one
AA from each of 150 DHS sibpairs (the sibling with the most complete phenotypic data and
best kidney function). The study was approved by the WFSM Institutional Review Board;
all participants provided written informed consent.
Multi-Ethnic Study of Atherosclerosis (MESA)—MESA investigates the prevalence,
correlates, and progression of subclinical CVD15. Recruitment was restricted to diabetic and
non-diabetic individuals free of clinical CVD. The cohort included participants with
previously and newly diagnosed diabetes. Data for this analysis were collected at baseline,
with exception of HbA1c collected at exam 2. MESA contributed data on 302 unrelated AA
participants.
Family Heart Study (FamHS)—A substudy of the Family Heart Study (FamHS) was
conducted to obtain cardiac CT scans for CAC16. University of Alabama in Birmingham
recruited AAs, some with T2DM. For this analysis, individuals with coronary artery bypass
surgery were excluded. FamHS contributed data on 103 unrelated AA participants.
Replication and validation efforts were conducted using existing genome-wide association
(GWAS) data in MESA SHARe and in the European-American DHS study. The MESA
SHARe data came from 1,350 non-diabetic AAs and 2,497 diabetic EAs. The diabetic AAs
were included in our discovery sample. Analyses in DHS were conducted on 920 EAs with
T2D.
In summary, analyses were performed on 1,040 unrelated AAs with T2DM, 1,350 unrelated
AAs without diabetes and 3,417 EAs with T2D. MESA diabetic EA participants were also
unrelated.
Genotyping of ancestry informative marker selection—DNA was extracted from
peripheral blood using PureGene system (Gentra Systems, Minneapolis, MN). The
streamlined panel of 1,509 ancestry informative markers (AIMs) was typed using the
Illumina AA admixture panel covering all 22 autosomes and chromosome X; analyses were
restricted to autosomes.
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Calcified plaque was measured in the coronary arteries using single and multidetector CT
systems incorporating a standardized scanning protocol based on the National Heart Lung
and Blood Institute’s MESA17. Traditionally, the Agatston or Calcium score was reported.
However, this scoring system adds noise to CT measurement of CP, compared to volume-
based measures. We use the calcium mass score (SmartScore, General Electric [GE]
Healthcare, Waukesha, WI) derived from the volume score, but also accounting for the
density of CP on a pixel-by-pixel basis. Additional scoring parameters included a 90
Hounsfield Unit (H.U.) threshold and 2 adjacent pixels to define the maximum calcified
lesion size and the program accounted for slice thickness.
Quality control
Quality control (QC checks similar to those performed in a GWAS were run before
performing the main analyses. Twenty-nine SNPs were flagged because Hardy-Weinberg
equilibrium testing had p-values <10−3, and 2 additional SNPs were flagged because their
call rate was <98% (none showed a significant result). Six individuals with call rates <90%
were dropped. We dropped one individual with a heterozygosity score outside the mean ± 4
times standard error (SE) confidence interval. There was no indication of first degree
familial relationships in the analyzed dataset. The estimated kinship coefficient ranged
between 0 and 0.13. Lower levels of familial relationship would be harder to detect with the
small number of markers. We did not pursue evaluation of familial relationships further.
Statistical methods
The RAM model that we applied is described in Redden et al.18. Briefly, for the ith
individual, let Yi denote the phenotype of interest, let P1i and P2i represent the ancestry of
proportions of this individual’s parents and finally, let I(Gij= k) denote dummy variables
indicating whether this individual has inherited exactly k copies of a particular allele from
an ancestral population at the jth marker. The RAM model can be written as:
(1)
where f( ) is the appropriate link function, and Ai is the individual ancestry (average of P1i
and P2i the ancestry proportion of the 2 parents of the ith individual). Note that P1i and P2i do
not have to be observed in order to fit this model. First, existing software will only provide
an estimate of Ai. Second, the product of parental ancestries can be estimated based on the
individual genotype (Redden et al. contains details on a maximum likelihood estimate of
(P1i P2i) that can be obtained without parental genotypes)18. Third, when the two parents
have similar ancestry proportion, as it is likely the case under assortative mating where
ancestry is closely linked with socioeconomic status, we have . We used
ADMIXMAP19 to compute these estimates. ADMIXMAP used a combination of Bayesian
and classical approaches to fit a multilevel model for the distribution of individual ancestry
proportion in the population and the stochastic variation of ancestry on hybrid
chromosomes.
In practice, I(Gij = k) where k=0, 1 or 2 and will not be available; however, the probability
of inheriting exactly 0, 1 or 2 alleles from a specific ancestral population can be estimated.
These probabilities are identity by descent (IBD) probabilities; therefore, equation (1) allows
for testing for linkage controlling for individual and parental ancestries20, 21. This model can
be fitted easily using standard statistical packages, facilitating inclusion of covariates and
interaction effects. Details regarding the computation of these probabilities based on the
observed genotypes and the estimated individual ancestry proportions are in the appendix.
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We use logarithm of odds (LOD) scores to present evidence against the null hypothesis to
reinforce the idea that we are performing linkage analysis.
Analyses were run using Log(CAC+1)as a continuous trait and CAC dichotomized
(individuals with CAC ≥10 treated as cases and CAC <10 as controls). This is justified
based on the assumption that factors governing presence of CAC may differ from those
influencing amount of CAC once calcification is initiated22. Age, gender and study were
included as covariates in Equation 1. Supplementary Table 1 suggests the distribution of
Hb1Ac, BMI, smoking status and use of lipid-lowering medication were statistically
different among the three studies. However, the model adjusted for age, gender and study
allowed to us to capture these differences.
Significant effect and correction for multiple testing
We excluded chromosome X from our analyses; therefore, the MALD analyses were run on
1,426 SNPS. A strict Bonferroni correction would place the significance threshold at
3.5×10−5 for a two-sided test, an excessively conservative threshold. We chose to prioritize
AIMs that reached a LOD score of 2.5 corresponding to an alpha level of 7 × 10−4. This
approach can be viewed as somewhat conservative for identifying suggestive evidence of
linkage. Following Reich and Patterson’s recommendation23, we also repeated the analyses
using the software ANCESTRYMAP24. The results were similar to our unadjusted analyses
and are not discussed further.
Fine mapping
To confirm the preliminary results, additional mapping was performed using a sparse set of
markers located on 3 chromosomal regions: 1p32.3, containing the largest LOD score
(LOD=3.7); 9p21.2 with a LOD of 2.7 and strong prior evidence of involvement in coronary
artery disease; and 11p15.4 with suggestive evidence of linkage (LOD score=2.5), the
lowest LOD score considered suggestive. SNPs for fine mapping were selected from
HapMap rel27 with preference given to AIMs with a delta-value of 0.5 or greater. We used
an r-squared threshold of 0.3 to minimize the LD among the 53 selected SNPs. Pairwise
linkage disequilibrium (LD) between markers was evaluated using Haploview25.
Genotyping was performed using the MassARRAY SNP Genotyping System (Sequenom
Inc., San Diego, CA)26. SNP genotyping was >94.4% efficient and 71 blind duplicates were
99.8% concordant. QC checks similar to those described herein identified two SNPs with
Hardy-Weinberg equilibrium test p-values <10−3. These analyses were conducted in the
discovery sample. Results obtained with these SNPs are shown in Supplementary Tables 5a,
5b and 5c.
Additional analyses in MESA
Approximately, one million SNPs are typed using the Affymetrix Genome-Wide Human
SNP Array 6.0. First, we focused on 1,350 non-diabetic AAs in MESA (diabetic AAs were
already included in our initial analysis). Second, we analyzed the 2,497 EA participants with
diabetes. We again conducted association tests between Log (CAC+1) and CAC as binary
outcome with a cutpoint of 10. SNPs were selected located 1,000 kb upstream and
downstream of the sentinel AIM that had a LOD score ≥2.5. SNPs were either directly
genotyped or imputed using IMPUTE27. Imputation in the EA sample was performed using
1,000 Genomes EUR (BCBI Build 37) as the reference panel and the combination HapMap I
+ HapMap II+CEU+YRI+CHB+JPT (BCBI Build 36) served as the reference panel in the
AA sample. We used the expected genotype (allelic dosage) for imputed SNPs. The analyses
were adjusted for age, sex, and individual admixture proportion. A Bonferroni correction
was applied in each region by dividing the nominal alpha level (5%) by the effective number
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of independent markers28. Therefore, the significance threshold was lower than the typical
threshold used for a whole-genome scan.
Analyses in European Americans from the Diabetes Heart Study
We genotyped SNPs located 1,000 kb upstream and downstream of each marker that had a
LOD score ≥2.5. Linear mixed effect models were fitted to account for the familial
correlation as measured by the realized kinship coefficient matrix. These models were fitted
using the GWAF package in R29 adjusting for age, gender and principal components. The
significance threshold was again established using the effective number of tests28.
Results
Demographic and clinical characteristics
Demographic and clinical characteristics of 1,040 unrelated AAs with T2DM from AA-
DHS, MESA, and FamHS have been reported previously 5, summarized in Table 1.
Participants had a mean (standard deviation; SD) age of 58.8 (10.2) years, diabetes duration
10.4 (8.5) years, HbA1c 7.9 (2.0) %, fasting serum glucose 153.8 (62.68) mg/dl, HDL-
cholesterol 48.1 (13.4) mg/dl, and LDL-cholesterol 109.8 (35.7) mg/dl. The mean (SD)
CAC mass score was 276.0 (628.7) H.U., with a median CAC mass score of 10 H.U.
Participants were 54.5% female, 23.7% were current and 35.6% former smokers.
Approximately 45% took lipid lowering medications, 36% insulin, and 42% angiotensin
converting enzyme inhibitors. Demographic and clinical characteristics of each study are
provided in Supplementary Table 1. Analyses were adjusted for study to account for
variations between the three cohorts. We repeated the analyses stratified by study and results
were similar to those observed in study-adjusted analyses (Supplementary Table 2).
Ancestry proportion distribution
The allele frequency of each AIM estimated in the Yoruban and CEPH populations were
supplied as prior probabilities in the estimation process. The average proportion of genome-
wide African ancestry in the combined sample was 80% (SD 11.5%). When the sample was
split based on a CAC cutpoint of 10 H.U., the average proportion of African ancestry was
79% for individuals with CAC ≥10 and 81% for CAC <10 (p-value=0.002). The association
between CAC and African ancestry proportion remained statistically significant after
adjusting for age, gender and study with an odds ratio 0.24 (p-value=0.02) when CAC was
analyzed as a binary outcome, and a parameter estimate β=−1.8 (p-value=0.01) when
Log(CAC+1)served as the outcome.
Regional admixture mapping results
Admixture mapping was performed using CAC mass score as a binary trait (Supplementary
Table 3), and as a continuous outcome (Supplementary Table 4). These complementary
analyses led to similar conclusions in most cases. When evidence of linkage was detected in
a region with both outcomes (quantity and presence), we focused only on the result observed
with the continuous outcome since the observed LOD scores tended to be greater. The result
with the lower p-value is reported in all cases. Results shown for presence (CAC ≥10 vs.
CAC <10) were only observed with this outcome, as presence and amount of CAC may be
governed by different processes30, 31. We considered the additive, dominant and recessive
models, allowing us to effectively reduce the models described in Equation 1 to 1 degree of
freedom tests, with potential improvement in power32. Adjusted p-values computed using
the maximum of the test statistic observed with the dominant, recessive and additive models
appeared to be one order of magnitude lower than their unadjusted counterparts33. SNPs at
1p32.3 (rs6663966, LOD=3.7), 4p21.2 (rs1712373, LOD=3.0), 8q22.2 (rs6994682,
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LOD=2.7), 9p21.2 (rs439314, LOD=2.7), and 13q32.1 (rs7492028, LOD=2.8) revealed
significant evidence of linkage with Log(CAC+1) . We also detected significant evidence of
linkage at 1q32.1 (rs7530895, LOD=3.1), 4q31.1 (rs1872861, LOD=2.7) and 11q25
(rs6590705, LOD=3.3) with the binary outcome. Results for these and other SNPs reaching
a LOD score ≥2.5 are summarized in Table 2. This Table also lists the average probability of
inheriting exactly two copies of the European derived allele at each marker. Based on the
global ancestry proportion estimate, the probability that an AA individual would inherit
exactly two alleles at random from the European population is 4%. For individuals with
CAC mass scores ≥10, we observed that the mean probability of inheriting exactly two
European-derived alleles at rs6994682, for example, was approximately 6.5%, more than
60% higher than the expected probability under the null. The observed mean was 4.1% in
those with CAC mass scores <10.
Regional admixture mapping results stratified by study
Analyses were repeated stratified by study, instead of accounting for study as in the initial
model. Supplementary Table 2 shows the study-specific LOD score and meta-analysis LOD
score for each SNP reaching a LOD ≥2.5 in the analysis adjusted for study. In general, the
two analysis strategies yielded similar results and would lead to similar inferences in most
cases. The AA-DHS specific LOD scores tended to be higher than those observed in the
other studies, except for rs9309717 and rs7933164 which had stronger LOD scores in
MESA (AA-DHS had a larger sample size). The extent to which the difference in sample
size explains differences in LOD scores is not clear. Ascertainment differences may also
contribute.
Fine mapping
Fine mapping was performed at 1p32.3 (highest LOD score 3.7), 9p21.2 with established
involvement in cardiac disease34–36, and 11p15.4 (lowest LOD score 2.5). Supplementary
Tables 5a–5c summarizes the admixture mapping results in these regions using an additional
set of AIMs typed around each sentinel SNP. The results of conditional analyses adjusted for
the sentinel AIM are included. Evidence of support for the linkage peak observed and
refinement of the interval on 1p32.3 was observed with four SNPs distal to the sentinel SNP
(rs6663966) showing nominal evidence of association (p-value<0.040; Supplementary Table
5a). Analysis of 19 additional AIMs on 9p21.2 also provided evidence of support for the
linkage observed. Twelve SNPs located around the sentinel SNP (rs439314) showing
evidence of association (P-value=0.034–4.5×10−4; Supplementary Table 5b). Finally,
sporadic evidence of support was observed with markers around the 11p15.4 sentinel SNP
(Supplementary Table 5c). In all three regions, conditional analyses accounting for the
sentinel SNP revealed that each signal was primarily driven by the previously identified
SNP with little evidence of additional AIMs contributing.
Analyses in other study samples
Results in additional samples are summarized in Supplementary Tables 6a and 6b, including
associated Manhattan plots. These plots show supportive evidence in identified regions;
indicating that the association is not likely an uncontrolled artifact. Analyses in the MESA
non-diabetic AA sample identified numerous nearby SNPs with p-values ranging between
10−3 and 10−4 in each region. The chromosome 8 region had a SNP whose p-value was
2.5×10−5 with additional supporting evidence around it. Results are shown in Figure 1a for
Log(CAC+1) and Figure 1b for presence of CAC.
We conducted association tests using available GWAS data on EAs in MESA and DHS.
Figure 2a shows that the strongest results in MESA EAs were on chromosome 11 near the
11p15.4 peak with several SNPs located near the sentinel marker with p-values between
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10−4 and 10−5. We also observed associations with Log(CAC+1) near 13q32.1 with p-values
between 10−3 and 10−4, and between the 2 sentinel makers on chromosome 1 with p-values
ranging between 0.01 and 0.001. There was no evidence of association nearthe 9p21.2
region. Results were similar when presence of CAC was used as the outcome except for the
chromosome 1 regions, which had p-values between 10−2 and 10−3 (See Figure 2b). As
shown in Figures 3a and 3b, DHS provided minimal evidence of support for genomic
regions from the initial analysis, with p-values 10−2 to 10−3. One SNP near 2p25.3 had
stronger evidence (p-value between 10−3 and 10−4).
We note that these SNPs would not meet genome-wide significance in a GWAS setting
under a strict Bonferroni correction threshold. However, considered in this context, they
strongly support initial results.
Discussion
Nearly all published reports demonstrate that AAs have lower amounts of CAC than EAs1–4.
CAC predicts risk of CVD death and myocardial infarction equally among members of all
population groups37, 38. Furthermore, AAs manifest lower levels of CAC despite greater
exposure to conventional CVD risk factors, supporting underlying inherited or biologic
mechanisms. The present analyses were directed at identifying genetic regions and variants
governing susceptibility to development and progression of CAC in diabetic AAs.
All AA participants with T2DM in the AA-DHS, MESA and FamHS cohorts with CAC
were included. Autosomal AIMs on the Illumina African American admixture panel were
genotyped and our RAM method applied to compute the probability of inheriting 0, 1 and 2
alleles from the ancestral European population. These probabilities were subsequently used
to test for linkage with CAC, analyzed as a continuous [Log(CAC+1)] and a binary trait
(cases had CAC ≥10). We note that the significant negative association between African
ancestry and CAC, replicating Wassel et al.’s sentinel observation6. This reverses the
longstanding concept that AAs are at higher CVD risk than EAs. In fact, AAs are at lower
biologic risk for myocardial infarction based on less CAC and they have significantly lower
rates of myocardial infarction than EAs provided equal access to healthcare39, 40. Lack of
healthcare access likely contributes to higher CVD rates in the general AA population. We
extend these results by pinpointing specific genomic regions where excess European
ancestry appears to confer higher risk for initiation of CAC, progression, or both.
The RAM analysis suggested regions on chromosomes 1, 2, 4, 8, 11 and 13 may harbor
genetic variants conferring higher level or odds of CAC. We also replicated the 9p region
associated with CVD in several ethnic groups. Significant novel associations with CAC
were observed on chromosomes 1, 4 and 11 with LOD scores between 3.0 and 3.7. Our
effort to replicate these findings is limited by the fact that few studies outside of the AA-
DHS, DHS and MESA have large scale genetic and computed tomography data on AAs
with T2DM. We extended our results in non-diabetic AAs from MESA. A limitation of our
validation approach is that, independently of the power of the test being conducted, the
meaning of a negative result is unclear. Null results may indicate the initial finding is false
positive or an interaction exists with diabetes that cannot be captured adequately in non-
diabetic samples.
The chromosome 1p32.3 linkage peak was located in GLIS family zinc finger 1 gene. This
SNP appeared to be monomorphic in the Centre d’Étude du Polymorphisme Humain
(CEPH) population and its minor allele frequency (MAF) in Yorubans is 26%. The MAF in
this sample is 42%. The low density lipoprotein receptor-related protein 8 gene (LRP8),
located ~200 Kb from this linkage peak and nearby genes remain of interest. LRP8 encodes
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an apolipoprotein E receptor, a member of the low density lipoprotein receptor family. The
apolipoprotein E receptor is involved in cellular recognition and internalization of
lipoproteins. LRP8 is associated with coronary artery disease in European-derived
populations. Admixture mapping peaks are generally not as well defined as GWAS signals.
Therefore, the GLIS1 signal is likely tracking the effect of other nearby gene(s). The second
chromosome 1 LOD peak is located at 1q32.1 near the chitotriosidase (CHIT1) gene. The
allele frequency at the tested marker is 97% and 33% in the CEPH and Yoruban HapMap 3
samples, respectively, relative to 43% in the study sample. A positive correlation between
chitotriosidase and atherosclerosis has been reported in European-derived samples41, 42 and
serum chitotriosidase activity may predict CVD events43.
Two regions on chromosome 4 had LOD scores ≥2.7. The first identified with Log(CAC
+1)with a LOD of 3.0 is 4p21.2 near the PRKG2 gene, a region including genes involved in
bone metabolism. Relationships between bone disease and arterial calcification are well
established, numerous studies report inverse relationships between bone mineral density
(BMD) and atherosclerosis in EAs and AAs44–46. The 9p21 region was previously
associated with coronary artery disease susceptibility in predominantly European-derived
populations36, 47, 48. AAs with excess European ancestry in this region had higher
prevalence and/or higher levels of CAC. The chromosome 11 and 13 peaks appear to be
novel in regards to this phenotype; further replication and validation efforts are needed.
Admixture mapping has limitations. These AIMs are not 100% informative and the
European ancestry at each marker is probabilistically determined. In addition, the power of
RAM is maximized when the average ancestry proportion from the two ancestral
populations is close to (0.50, 0.50); these proportions were estimated to be approximately
(0.80, 0.20) in this sample. Nonetheless, admixture mapping remains a valuable and proven
gene-mapping technique. In fact, combining admixture mapping and association tests can
lead to non-negligible gain in power11.
In addition to fine mapping the genome-wide significant linkage peaks, attention should be
paid to underlying candidate genes involved in vitamin D metabolism, calcium handling and
bone health. We demonstrated inverse relationships between CAC and BMD in the AA-
DH49. Thus, susceptibility to osteoporosis and development of CAC appear to be linked in
EAs and AAs. CYP2R1, an enzyme important in activation of vitamin D, is located under
the chromosome 11 MALD peak. BMP3 and PRKG2, involved in multiple aspects of
cartilage and bone development, are located under the chromosome 4 MALD peak.
Additional genes under these MALD peaks with involvement in calcium, bone and arterial
metabolism include chromosomes 1 (ADORA1, BTG2, FMOD, and PRELP) and 8
(RNF19A). It is likely that population-specific susceptibility to CAC reflects, in part, the
widely appreciated racial differences in calcium and vitamin D metabolism50.
In conclusion, genomic regions on chromosomes 1, 2, 4, 8, 9, 11 and 13 identified by
admixture mapping appear to contribute to ethnic differences in susceptibility to CAC
between AAs and EAs. Fine mapping under these peaks is likely to detect causative genes,
potentially leading to improved understanding of the biologic causes of this phenomenon
and development of novel anti-atherosclerotic therapies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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African Americans (AAs) have markedly lower levels of coronary artery calcified
atherosclerotic plaque (CAC) than European Americans (EAs), despite the presence of
more severe conventional cardiovascular disease risk factors. These findings suggest that
inherited or biologic factors underlie susceptibility to CAC, a measure of subclinical
coronary artery disease. In an effort to detect genes underlying susceptibility to CAC, we
performed regional admixture mapping (RAM) in 1,040 unrelated AAs with type 2
diabetes who had computed tomography-derived measures of CAC. RAM is a gene
mapping technique useful for detecting disease genes in admixed populations. RAM is
particularly powerful when the disease prevalence or distribution of the trait of interest
varies substantially between the ancestral populations. RAM revealed 11 genomic
regions located on chromosomes 1, 2, 4, 8, 9, 11 and 13 that were significantly or
suggestively linked with the presence or severity of CAC in AAs. Strikingly, all eleven
regions displayed higher than expected European ancestry in individuals whose CAC
score was 10 or higher. These results underscore that susceptibility to coronary artery
disease in the admixed AA population relates to European ancestry. Fine mapping under
these linkage peaks is likely to detect the genes that regulate the related processes of
atherosclerotic coronary artery disease and vascular calcification.
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Figure 1A: Genetic association results in non-diabetic African Americans in MESA using
Log(CAC+1) as the outcome and genotyped and imputed SNPs found 500 kb upstream and
downstream of the sentinel marker in each region. B: Genetic association results in non-
diabetic African Americans in MESA using presence of CAC as the outcome and genotyped
and imputed SNPs found 500 kb upstream and downstream of the sentinel marker in each
region.
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Figure 2A: Genetic association results in European Americans in MESA using Log (CAC
+1) as the outcome and genotyped and imputed SNPs found 500 kb upstream and
downstream of the sentinel marker in each region. B: Genetic association results in
European Americans in MESA using presence of CAC as the outcome and genotyped and
imputed SNPs found 500 kb upstream and downstream of the sentinel marker in each
region.
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Figure 3A: Genetic association results in European Americans in DHS using Log (CAC+1)
as the outcome and genotyped SNPs found 500 kb upstream and downstream of the sentinel
marker in each region. B: Genetic association results in European Americans in DHS using
presence of CAC as the outcome genotyped and imputed SNPs found 500 kb upstream and
downstream of the sentinel marker in each region.
Note: Straight vertical lines inside each chromosomal region represent the sentinel AIM for
which initial results were observed in all figures.
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